Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|June 20, 2016
Clinical advice from the latest ARMOR study update
In the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully.
Advertisement
In the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully. âUse the information that is available,â Dr. Asbell encouraged, adding that the ARMOR study offers up-to-date information on resistance patterns so clinicians will understand which antibiotics work most effectively.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Alvotech files first known aflibercept 8 mg biosimilar with EMA
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5